Fixation of Retail prices of 33 formulation, 09 Ceiling price and 5 Special feature product approved in 118 Authority meeting

7098 GI/202 3 (1) EXTRAORDINARY PART II —Section 3 —Sub-section ( ii) PUBLISHED BY AUTHORITY (1) (2) (3) (4) (5) (6) No. 4683] NEW DELHI, FRIDAY , NOVEMBER 10 , 2023/ KARTIKA 19, 1945 CG-DL-E-10112023-250014 (1) (2) (3) (4) (5) (6) (1) (2) (3) (4) (5) (6) (1) (2) (3) (4) (5) (6) (1) (2) (3) (4) (5) (6) (6) V (4) I MINISTRY OF CHEMICALS AND FERTILIZERS (Depar tment of Pharmaceuticals ) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 10th November , 2023 S.O. 4 885(E).— In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249 (E) dated 11th November , 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entrie s in columns (3), (4) and (5) thereof; TABLE Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1 Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet Each film coated bilayered tablet contains : Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended release) Telmisartan IP 40mg, Cilnidipine IP 10mg 1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. 10.04 2 Amoxycillin + Potassium Clavulanate Oral Suspension Each combi pack contains: (A) Amoxycillin and Potassium Clavulanate Oral Suspension IP Each 5ml of Re constituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 57mg (B) Sterile water for Reconsitution - 30 ml 1 ml M/s Malik Life Sciences Pvt. Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. 4.16 3 Vildagliptin + Metformin Hydrochloride Tablet Each film coated ta blet contains: Vildagliptin IP 50mg Metformin Hydrochloride IP 1000mg 1 Tablet M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. 8.32 4 Vildagliptin + Metformin Hydrochloride Tablet Each film coated tablet contains: Vildagliptin IP 50mg Metformin Hydrochloride IP 500mg 1 Tablet M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. 7.89 5 Telmisartan and Bisoprolol Fumarate Tablets Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg 1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. 9.62 6 Telmisartan and Bisoprolol Fumarate Tablets Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg 1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. 11.31 7 Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50 mg (As Extended release) Telmisartan IP 40mg, Cilnidipine IP 10mg 1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. 12.46 8 Atorvastatin & Ezetimibe Tablets Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg Ezetimibe IP 10mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited 23.85 9 Atorvastatin & Ezetimibe Tablets Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorva statin 40mg Ezetimibe IP 10mg 1 Tablet M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited 32.61 10 Cholecalciferol (Vitamin D3) Oral Solution 60000IU Each 5ml Syrup contains: Cholecalciferol 60000 IU 1 ml M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited 12.27 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 11 Telmisartan and Metoprolol Succinate (ER) Tablet Each film coated bilayered tablet contains: Telmisartan IP 40mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (as extended -release form) 1 Tablet M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. 11.96 12 Ceftriaxone & Sulbactam for Injection Each vial contains: Sterile Ceftriaxone Sodium IP eq. to Ceftriaxone 1000mg Sterile Sulbactam Sodium IP eq. to Sulbactam 500mg 1 vial M/s Scott -Edil Advance Research Laboratories and Eduction Ltd. / M/s J.B. Chemicals & Pharmaceuticals Ltd. 142.48 13 Bisoprolol Fumarate & Amlodipine tablet Each film coated tablet contains: Bisoprolol Fumarate IP 2.5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg 1 Tablet M/s Unison Pharmaceuticals Pvt. Ltd. 6.19 14 Bisoprolol Fumarate & Amlodipine tablet Each film coated tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg 1 Tablet M/s Unison Pharmaceuticals P vt. Ltd. 8.34 15 Amoxycillin & Potassium Clavulanate Oral Suspension IP Each 5ml (after reconstitution) contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg Potassium Clavulanate diluted IP eq. to Clavulanic Acid 57mg 1 ml M/s Uni Medico Labs / M/s Torrent Pharmaceuticals Ltd. 4.20 16 Diclofenac Diethylamine, Methyl Salicylate, Menthol & Virgin Linseed Oil Topical Spray Composition: Diclofenac Diethylamine IP 1.16%w/w eq. to Diclofenac Sodium IP 1% w/w Virgin Linseed Oil BP 3% w/w Methyl Salicyl ate IP 10% w/w Menthol IP 5%w/w 1 Gram M/s Pontika Aerotech Limited / M/s Blue Cross Laboratories Pvt. Ltd. 2.83 17 Rabeprazole Sodium and Domperidone SR Capsules Each hard gelatin capsule contains: Rabeprazole Sodium IP 20mg (As enteric coated pellets) Domperidone IP 30mg (as Sustained release pellets) 1 Capsule M/s Aagya Biotech Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd. 11.52 18 Metronidazole, Lignocaine Hydrochloride and Chlorhexidine Gluconate Gel Contains : Metronidazole Benzoate IP Metronidazole 1 % w/w Lignocaine Hydrochloride IP 2% w/w Chlorhexidine Gluconate Solution Chlorhexidine Gluconate 1% w/w 1 Gram M/s J.B. Chemicals & Pharmaceuticals Ltd. 4.22 19 Rosuvastatin + Clopidogrel Capsules Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 1 Capsule M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. 19.21 20 Rosuvastatin + Clopidogrel Capsules Each ha rd gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 1 Capsule M/s Skymap Pharmaceuticals Pvt. Ltd. 19.21 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 21 Rosuvastatin + Clopidogrel Capsules Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 1 Capsule M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. 19.21 22 Telmisarta n and Bisoprolol Fumarate Tablets Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg 1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zydus Healthcare Ltd. 11.36 23 Telmisartan and Bisoprolol Fumarate Tablets Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg 1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zydus Healthcare Ltd. 9.69 24 Hydroxychloroquine Sulphate tablet Each film coated tabley contains: Hydroxychloroquine Sulphate IP 300mg 1 Tablet M/s Innova Captab Ltd. / M/s Brinton Pharmaceuticals Limited 13.54 25 Ibuprofen Injection Each ml contains: Ibuprofen IP 100mg 1 ml M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. 26.78 26 Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine maleate, Ammonium Chloride, Sodium Citrate & Menthol Suspenssion Each 5ml contains: Paracetamol IP 250mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine maleate IP 2mg Ammonium Chloride IP 120mg Sodium Citrate IP 60mg Menthol IP 1mg 1 ml M/s Windlas Biotech Limited / M/s Intas Pharmaceuticals Ltd. 0.82 27 Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydro chloride IP 1000mg Glimepiride IP 1 mg 1 Tablet M/s Sun Pharma Laboratories Limited 13.10 28 Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 5 0mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg 1 Tablet M/s Sun Pharma Laboratories Limited 14.60 29 Linagliptin + Metformin Hydrochloride (ER) Tablet Each film coated bilayer tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg 1 Tablet M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited 14.37 30 Budesonide , Glycopyrronium and Formoterol Fumarate Dihydrate Inhal er Each actuation delivers: Budesonide IP 200mcg Glycopyrronium (as Glycopyrrolate IP) 12.5mcg Formoterol Fumarate Dihydrate suspended in propellant IP 6mcg Per pack of 120 MDI M/s Cipla Limited 855.00 31 Insulin Glargine 100IU /ml and Lixisenatide 50mcg/ml Each Prefilled pen containing: Fixed Ratio combination of Insulin Glargine 100IU /ml Lixisenatide 50mcg/ml 1ml M/s Sanofi Healthcare India Pvt. Ltd. / M/s Sanofi India Limited 587.30 Sl. No. Name of the Formulation / Brand Name Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 32 Insulin Glargine 100IU /ml and Lixisenatide 33mcg/m Each Prefilled pen containing: Fixed Ratio combination of Insulin Glargine 100IU /ml Lixisenatide 33mcg/ml 1ml M/s Sanofi Healthcare India Pvt. Ltd. / M/s Sanofi India Limited 587.30 33 Combikit of Atazanavir + Ritonavir & Emtricitabine + Tenofovir Alafenamide Tablet Each Combi kit contains : Part A: Each film coated tablet contains: Atazanavir Sulphate IP eq. to Atazanavir 300mg Ritonavir IP 100mg Part B: Each film coated tablet contains: Emtricitabine IP 200mg Tenofovir Alafenamide Fumarate eq. to Tenofovir Alafenamide 10mg 1 Combi kit M/s Emcure Pharmaceuticals Limited 112.60 Note: (a) The manufacturer of above -mentioned formulations i.e., “new drug” under para graph 2 (1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentione d in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2 013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person w ishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / market er as mentioned above i.e. who have applied for the same by submitting Form -I for price fixation / revision as stipulated under DPCO, 201 3 and subject to fulfilment of all the applicable statutory r equirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer /marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketin g company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the fixation of retail price of such formulation as specified i n column (2) of the above table with the strength and name of Manufactur er & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for t hat Manufactur er & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded. [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) 4, 6, 10, 11, 14, 16, (1) (2) (3) (4) (5) (5) (2) (5) V (4) (1) II I II III II IV ORDER New Delhi, the 10th November , 2023 S.O. 4 886(E).— In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO 1573(E) dated 31st March, 2023 in so far as it relates to formulation p acks mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respective ly in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. No. Name of the Scheduled Formulation Dosage form and strength Unit Ceiling Price (Rs.) (1) (2) (3) (4) (5) 1 Tacrolimus Tablet 1mg 1 Tablet 39.98 2 Tacrolimus Tablet 2mg 1 Tabl et 77.69 3 Tacrolimus Tablet 0.5mg 1 Tablet 20.97 4 Co-trimoxazole [Sulphamethoxazole (A)+Trimethoprim (B)] Tablet 800mg (A) + 160 mg (B) 1 Tablet 2.30 5 Zinc Sulphate Dispersible Tablet 20mg 1 Tablet 3.41 6 Tramadol Tablet 50mg 1 Tablet 9.70 7 Trama dol Tablet 100mg 1 Tablet 24.48 8 Temozolomide Tablet 20 mg 1 Tablet 336.63 9 Temozolomide Tablet 250 mg 1 Tablet 3757.94 Note: (a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations a t a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above tabl e plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above -mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if a ny, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013. (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form –V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily access ible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacture r shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule -II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / im port and sale of scheduled formulations in Form -III of Schedule -II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuatio n of production and / or import of scheduled formulation in Form -IV of Schedule -II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove s hall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) (1) (2) (3) ADDENDUM New Delhi, the 10th November , 2023 S.O. 4 887(E).—The National Pharmaceutical Pricing Authority’s Order No. 1571(E) dated 31st March 2023, published in the Gazette of India, Extraordinary, related to ceiling price fixation of scheduled formulation packs of I.V. fluids (non -Glass with special features) is henceforth to be read with the following additions: (1) Sl. No. 25 shall be added in Table ‘B’ as below: Sl. No. Name of Manufacturer Product/ Brand Name (1) (2) (3) 25. M/s Biosynergy Lifecare Pvt. Ltd. BIOPORT (2) Clause (e1) is added after clause (e) & shall be read as follows: “ (e1) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 25 of Table B, only the prices of the formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable .” (3) Sl. No. 5 of Table ‘A’of S.O. No. 1571(E) dated 31st March 2023 is also added for clause (d), accordingly clause (d) shall be read as follows: “ (d) In case of M/s Puerto Life Sciences Private Limited m entioned in Sl. No. 23 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable .” [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) (1) (2) ADDENDUM New Delhi, the 10th November , 2023 S.O. 4 888(E).—The National Pharmaceutical Pricing Authority’s Order No. 1570(E) dated 31st March 2023, published in the Gazette of India, Extraordinary, related to ceiling price fixation of Ringer lactate injection in pack having special features is henceforth to be read with the following additions: (1) Sl. No. 18 shall be added in Table ‘B’ as below: Sl. No. Name of Manufacturer (1) (2) 18. M/s Biosynergy Lifecare Pvt. Ltd. (Brand name “BIOPORT ”) (2) Clause (d1) is added after clause (d) & shall be read as follows: “ (d1) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 1 8 of Table B, only the prices of the formulations specified in Sl. No. 3 & 4 of Table A are applicable .” [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) (1) (2) ADDENDUM New Delhi, the 10th November , 2023 S.O. 4 889(E).—The National Pharmaceutical Pricing Authority’s Order No. 1576(E) dated 31st March 2023, published in the Gazette of India, Extraordinary, related to ceiling price fixation of the scheduled formulation as specified therein is henceforth to be read with the following additions: (1) Sl.No. 5 shall be added in Table ‘B’ as below: Sl. No. Name of Manufacturer (1) (2) 5. M/s Biosynergy Lifecare Pvt. Ltd. [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) (1) (2) ADDENDUM New Delhi, the 10th November , 2023 S.O. 4 890(E).—The National Pharmaceutical Pricing Authority’s Order No. 1575(E) dated 31st March 2023, published in the Gazette of India, Extraordinary, related to ceiling price fixatio n of the scheduled formulation as specified therein is henceforth to be read with the following additions: (1) Sl.No. 5 shall be added in Table ‘B’ as below: Sl. No. Name of Manufacturer (1) (2) 5. M/s Biosynergy Lifecare Pvt. Ltd. [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) (1) (2) ADDENDUM New Delhi, the 10th November , 2023 S.O. 4 891(E).— The National Pharmaceutical Pricing Authority’s Order No. 1569(E) dated 31st March 2023, published in the Gazette of India, Extraordina ry, related to ceiling price fixation of the scheduled formulation as specified therein is henceforth to be read with the following additions: (1) Sl. No. 5 shall be added in Table ‘B’ as below: Sl. No. Name of Manufacturer (1) (2) 5. M/s Biosynergy Li fecare Pvt. Ltd. [PN/250/118/2023/F F. No. 8(118)/2023/D.P./NPPA -Div.-II] MAHAVEER SAINI , Dy. Director (Pricing) Uploaded by Dte. of Printing at Government of India Press, Ring R oad, Mayapuri, New Delhi -110064 and Published by the Controller of Publications, Delhi -110054.